Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

Overview of attention for article published in BMC Cancer, January 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog

twitter: 16 X users

Citations

dimensions_citation: 36 Dimensions

Readers on

mendeley: 74 Mendeley

Summary News Blogs X Dimensions citations

So far, Altmetric has seen 2 posts from 1 blogs.

#VisualAbstract: Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer

Physician's Weekly, 06 Jan 2024

1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR of 0.66. 2.

Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer

Physician's Weekly, 26 Dec 2023

1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR of 0.66. 2.

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.